LLY
Eli Lilly and Company · Healthcare · Drug Manufacturers - General
مدخلات الزخم (المديرون المماثلون):
اتساع نطاق المالكين -10.0% ·
تدفق الأسهم -2.5% ·
المراكز الجديدة الصافية -14.8%
— الصيغة
توزيع واسع — انخفاض الأسهم وتراجع عدد المالكين
جميع أرقام الملكية: مديرو 13F المتتبَّعون فقط، مراكز الأسهم العادية، فترة إعداد التقارير Q3 2025
| الربع | الملّاك | Δ | الأسهم | القيمة المُبلَّغ عنها | جديد | الخروجات |
|---|---|---|---|---|---|---|
| Q2 2026 | 193 | +4 | 671.92M | $804.91B | +6 | −1 |
| Q1 2026 | 191 | -3 | 666.59M | $613.20B | +1 | −5 |
| Q4 2025 | 193 | +2 | 707.04M | $758.81B | +3 | — |
| Q3 2025 | 27 | -3 | 329.88M | $251.63B | +2 | −6 |
| Q2 2025 | 28 | -1 | 307.45M | $239.60B | +2 | −3 |
| Q1 2025 | 26 | 0 | 140.32M | $115.83B | +1 | −1 |
| Q4 2024 | 26 | +1 | 145.00M | $111.91B | +3 | −2 |
| Q3 2024 | 24 | +2 | 109.89M | $97.29B | +2 | — |
| Q2 2024 | 22 | — | 112.43M | $101.75B | — | — |
| # | المدير | الأسهم | Δ الأسهم | القيمة | وزنها | محتفظ به | ||
|---|---|---|---|---|---|---|---|---|
| 1 | The Vanguard Group ✦ (سلبي) | 80.96M | +0.7% | $61.77B | 0.9% | ▲ Add | 2 | SEC ↗ |
| 2 | The Vanguard Group ✦ (سلبي) | 80.96M | +0.7% | $61.77B | 0.9% | ▲ Add | 2 | SEC ↗ |
| 3 | The Vanguard Group ✦ (سلبي) | 80.96M | +0.7% | $61.77B | 0.9% | ▲ Add | 2 | SEC ↗ |
| 4 | The Vanguard Group ✦ (سلبي) | 80.96M | +0.7% | $61.77B | 0.9% | ▲ Add | 2 | SEC ↗ |
| 5 | The Vanguard Group ✦ (سلبي) | 80.96M | +0.7% | $61.77B | 0.9% | ▲ Add | 2 | SEC ↗ |
| 6 | The Vanguard Group ✦ (سلبي) | 80.96M | +0.7% | $61.77B | 0.9% | ▲ Add | 2 | SEC ↗ |
| 7 | The Vanguard Group ✦ (سلبي) | 80.96M | +0.7% | $61.77B | 0.9% | ▲ Add | 2 | SEC ↗ |
| 8 | BlackRock ✦ (سلبي) | 65.81M | -0.2% | $50.21B | 0.9% | ▼ Trim | 2 | SEC ↗ |
| 9 | BlackRock ✦ (سلبي) | 65.81M | -0.2% | $50.21B | 0.9% | ▼ Trim | 2 | SEC ↗ |
| 10 | BlackRock ✦ (سلبي) | 65.81M | -0.2% | $50.21B | 0.9% | ▼ Trim | 2 | SEC ↗ |
| 11 | BlackRock ✦ (سلبي) | 65.81M | -0.2% | $50.21B | 0.9% | ▼ Trim | 2 | SEC ↗ |
| 12 | BlackRock ✦ (سلبي) | 65.81M | -0.2% | $50.21B | 0.9% | ▼ Trim | 2 | SEC ↗ |
| 13 | BlackRock ✦ (سلبي) | 65.81M | -0.2% | $50.21B | 0.9% | ▼ Trim | 2 | SEC ↗ |
| 14 | BlackRock ✦ (سلبي) | 65.81M | -0.2% | $50.21B | 0.9% | ▼ Trim | 2 | SEC ↗ |
| 15 | BlackRock ✦ (سلبي) | 65.81M | -0.2% | $50.21B | 0.9% | ▼ Trim | 2 | SEC ↗ |
| 16 | BlackRock ✦ (سلبي) | 65.81M | -0.2% | $50.21B | 0.9% | ▼ Trim | 2 | SEC ↗ |
| 17 | BlackRock ✦ (سلبي) | 65.81M | -0.2% | $50.21B | 0.9% | ▼ Trim | 2 | SEC ↗ |
| 18 | BlackRock ✦ (سلبي) | 65.81M | -0.2% | $50.21B | 0.9% | ▼ Trim | 2 | SEC ↗ |
| 19 | BlackRock ✦ (سلبي) | 65.81M | -0.2% | $50.21B | 0.9% | ▼ Trim | 2 | SEC ↗ |
| 20 | BlackRock ✦ (سلبي) | 65.81M | -0.2% | $50.21B | 0.9% | ▼ Trim | 2 | SEC ↗ |
| 21 | BlackRock ✦ (سلبي) | 65.81M | -0.2% | $50.21B | 0.9% | ▼ Trim | 2 | SEC ↗ |
| 22 | BlackRock ✦ (سلبي) | 65.81M | -0.2% | $50.21B | 0.9% | ▼ Trim | 2 | SEC ↗ |
| 23 | BlackRock ✦ (سلبي) | 65.81M | -0.2% | $50.21B | 0.9% | ▼ Trim | 2 | SEC ↗ |
| 24 | BlackRock ✦ (سلبي) | 65.81M | -0.2% | $50.21B | 0.9% | ▼ Trim | 2 | SEC ↗ |
| 25 | BlackRock ✦ (سلبي) | 65.81M | -0.2% | $50.21B | 0.9% | ▼ Trim | 2 | SEC ↗ |
| 26 | BlackRock ✦ (سلبي) | 65.81M | -0.2% | $50.21B | 0.9% | ▼ Trim | 2 | SEC ↗ |
| 27 | BlackRock ✦ (سلبي) | 65.81M | -0.2% | $50.21B | 0.9% | ▼ Trim | 2 | SEC ↗ |
| 28 | BlackRock ✦ (سلبي) | 65.81M | -0.2% | $50.21B | 0.9% | ▼ Trim | 2 | SEC ↗ |
| 29 | BlackRock ✦ (سلبي) | 65.81M | -0.2% | $50.21B | 0.9% | ▼ Trim | 2 | SEC ↗ |
| 30 | BlackRock ✦ (سلبي) | 65.81M | -0.2% | $50.21B | 0.9% | ▼ Trim | 2 | SEC ↗ |
| 31 | State Street Global Advisors ✦ (سلبي) | 34.73M | +0.6% | $26.50B | 0.9% | ▲ Add | 4 | SEC ↗ |
| 32 | Fidelity (FMR) ✦ | 24.17M | -5.7% | $18.44B | 1.0% | ▼ Trim | 2 | SEC ↗ |
| 33 | Fidelity (FMR) ✦ | 24.17M | -5.7% | $18.44B | 1.0% | ▼ Trim | 2 | SEC ↗ |
| 34 | Fidelity (FMR) ✦ | 24.17M | -5.7% | $18.44B | 1.0% | ▼ Trim | 2 | SEC ↗ |
| 35 | Fidelity (FMR) ✦ | 24.17M | -5.7% | $18.44B | 1.0% | ▼ Trim | 2 | SEC ↗ |
| 36 | Fidelity (FMR) ✦ | 24.17M | -5.7% | $18.44B | 1.0% | ▼ Trim | 2 | SEC ↗ |
| 37 | Fidelity (FMR) ✦ | 24.17M | -5.7% | $18.44B | 1.0% | ▼ Trim | 2 | SEC ↗ |
| 38 | JPMorgan Chase ✦ | 20.54M | — | $15.67B | 0.5% | n/c | 1 | SEC ↗ |
| 39 | JPMorgan Chase ✦ | 20.54M | — | $15.67B | 0.5% | n/c | 1 | SEC ↗ |
| 40 | JPMorgan Chase ✦ | 20.54M | — | $15.67B | 0.5% | n/c | 1 | SEC ↗ |
| 41 | JPMorgan Chase ✦ | 20.54M | — | $15.67B | 0.5% | n/c | 1 | SEC ↗ |
| 42 | JPMorgan Chase ✦ | 20.54M | — | $15.67B | 0.5% | n/c | 1 | SEC ↗ |
| 43 | JPMorgan Chase ✦ | 20.54M | — | $15.67B | 0.5% | n/c | 1 | SEC ↗ |
| 44 | JPMorgan Chase ✦ | 20.54M | — | $15.67B | 0.5% | n/c | 1 | SEC ↗ |
| 45 | JPMorgan Chase ✦ | 20.54M | — | $15.67B | 0.5% | n/c | 1 | SEC ↗ |
| 46 | JPMorgan Chase ✦ | 20.54M | — | $15.67B | 0.5% | n/c | 1 | SEC ↗ |
| 47 | JPMorgan Chase ✦ | 20.54M | — | $15.67B | 0.5% | n/c | 1 | SEC ↗ |
| 48 | JPMorgan Chase ✦ | 20.54M | — | $15.67B | 0.5% | n/c | 1 | SEC ↗ |
| 49 | JPMorgan Chase ✦ | 20.54M | — | $15.67B | 0.5% | n/c | 1 | SEC ↗ |
| 50 | JPMorgan Chase ✦ | 20.54M | — | $15.67B | 0.5% | n/c | 1 | SEC ↗ |
| 51 | JPMorgan Chase ✦ | 20.54M | — | $15.67B | 0.5% | n/c | 1 | SEC ↗ |
| 52 | JPMorgan Chase ✦ | 20.54M | — | $15.67B | 0.5% | n/c | 1 | SEC ↗ |
| 53 | JPMorgan Chase ✦ | 20.54M | — | $15.67B | 0.5% | n/c | 1 | SEC ↗ |
| 54 | JPMorgan Chase ✦ | 20.54M | — | $15.67B | 0.5% | n/c | 1 | SEC ↗ |
| 55 | JPMorgan Chase ✦ | 20.54M | — | $15.67B | 0.5% | n/c | 1 | SEC ↗ |
| 56 | JPMorgan Chase ✦ | 20.54M | — | $15.67B | 0.5% | n/c | 1 | SEC ↗ |
| 57 | JPMorgan Chase ✦ | 20.54M | — | $15.67B | 0.5% | n/c | 1 | SEC ↗ |
| 58 | JPMorgan Chase ✦ | 20.54M | — | $15.67B | 0.5% | n/c | 1 | SEC ↗ |
| 59 | JPMorgan Chase ✦ | 20.54M | — | $15.67B | 0.5% | n/c | 1 | SEC ↗ |
| 60 | JPMorgan Chase ✦ | 20.54M | — | $15.67B | 0.5% | n/c | 1 | SEC ↗ |
| 61 | JPMorgan Chase ✦ | 20.54M | — | $15.67B | 0.5% | n/c | 1 | SEC ↗ |
| 62 | JPMorgan Chase ✦ | 20.54M | — | $15.67B | 0.5% | n/c | 1 | SEC ↗ |
| 63 | JPMorgan Chase ✦ | 20.54M | — | $15.67B | 0.5% | n/c | 1 | SEC ↗ |
| 64 | JPMorgan Chase ✦ | 20.54M | — | $15.67B | 0.5% | n/c | 1 | SEC ↗ |
| 65 | JPMorgan Chase ✦ | 20.54M | — | $15.67B | 0.5% | n/c | 1 | SEC ↗ |
| 66 | JPMorgan Chase ✦ | 20.54M | — | $15.67B | 0.5% | n/c | 1 | SEC ↗ |
| 67 | JPMorgan Chase ✦ | 20.54M | — | $15.67B | 0.5% | n/c | 1 | SEC ↗ |
| 68 | JPMorgan Chase ✦ | 20.54M | — | $15.67B | 0.5% | n/c | 1 | SEC ↗ |
| 69 | JPMorgan Chase ✦ | 20.54M | — | $15.67B | 0.5% | n/c | 1 | SEC ↗ |
| 70 | JPMorgan Chase ✦ | 20.54M | — | $15.67B | 0.5% | n/c | 1 | SEC ↗ |
| 71 | JPMorgan Chase ✦ | 20.54M | — | $15.67B | 0.5% | n/c | 1 | SEC ↗ |
| 72 | JPMorgan Chase ✦ | 20.54M | — | $15.67B | 0.5% | n/c | 1 | SEC ↗ |
| 73 | JPMorgan Chase ✦ | 20.54M | — | $15.67B | 0.5% | n/c | 1 | SEC ↗ |
| 74 | JPMorgan Chase ✦ | 20.54M | — | $15.67B | 0.5% | n/c | 1 | SEC ↗ |
| 75 | JPMorgan Chase ✦ | 20.54M | — | $15.67B | 0.5% | n/c | 1 | SEC ↗ |
| 76 | JPMorgan Chase ✦ | 20.54M | — | $15.67B | 0.5% | n/c | 1 | SEC ↗ |
| 77 | JPMorgan Chase ✦ | 20.54M | — | $15.67B | 0.5% | n/c | 1 | SEC ↗ |
| 78 | JPMorgan Chase ✦ | 20.54M | — | $15.67B | 0.5% | n/c | 1 | SEC ↗ |
| 79 | JPMorgan Chase ✦ | 20.54M | — | $15.67B | 0.5% | n/c | 1 | SEC ↗ |
| 80 | JPMorgan Chase ✦ | 20.54M | — | $15.67B | 0.5% | n/c | 1 | SEC ↗ |
| 81 | JPMorgan Chase ✦ | 20.54M | — | $15.67B | 0.5% | n/c | 1 | SEC ↗ |
| 82 | Geode Capital Management ✦ (سلبي) | 19.82M | +9.3% | $15.07B | 1.0% | ▲ Add | 6 | SEC ↗ |
| 83 | Geode Capital Management ✦ (سلبي) | 19.82M | +9.3% | $15.07B | 1.0% | ▲ Add | 6 | SEC ↗ |
| 84 | Morgan Stanley ✦ | 15.19M | — | $11.59B | 0.7% | n/c | 1 | SEC ↗ |
| 85 | Morgan Stanley ✦ | 15.19M | — | $11.59B | 0.7% | n/c | 1 | SEC ↗ |
| 86 | Morgan Stanley ✦ | 15.19M | — | $11.59B | 0.7% | n/c | 1 | SEC ↗ |
| 87 | Morgan Stanley ✦ | 15.19M | — | $11.59B | 0.7% | n/c | 1 | SEC ↗ |
| 88 | Morgan Stanley ✦ | 15.19M | — | $11.59B | 0.7% | n/c | 1 | SEC ↗ |
| 89 | Morgan Stanley ✦ | 15.19M | — | $11.59B | 0.7% | n/c | 1 | SEC ↗ |
| 90 | Morgan Stanley ✦ | 15.19M | — | $11.59B | 0.7% | n/c | 1 | SEC ↗ |
| 91 | Morgan Stanley ✦ | 15.19M | — | $11.59B | 0.7% | n/c | 1 | SEC ↗ |
| 92 | Morgan Stanley ✦ | 15.19M | — | $11.59B | 0.7% | n/c | 1 | SEC ↗ |
| 93 | Morgan Stanley ✦ | 15.19M | — | $11.59B | 0.7% | n/c | 1 | SEC ↗ |
| 94 | Morgan Stanley ✦ | 15.19M | — | $11.59B | 0.7% | n/c | 1 | SEC ↗ |
| 95 | Morgan Stanley ✦ | 15.19M | — | $11.59B | 0.7% | n/c | 1 | SEC ↗ |
| 96 | Morgan Stanley ✦ | 15.19M | — | $11.59B | 0.7% | n/c | 1 | SEC ↗ |
| 97 | Morgan Stanley ✦ | 15.19M | — | $11.59B | 0.7% | n/c | 1 | SEC ↗ |
| 98 | Morgan Stanley ✦ | 15.19M | — | $11.59B | 0.7% | n/c | 1 | SEC ↗ |
| 99 | Morgan Stanley ✦ | 15.19M | — | $11.59B | 0.7% | n/c | 1 | SEC ↗ |
| 100 | Morgan Stanley ✦ | 15.19M | — | $11.59B | 0.7% | n/c | 1 | SEC ↗ |
"وزنهم" = حصة المركز من إجمالي قيمة حقوق الملكية 13F المُبلَّغ عنها لدى ذلك المدير — مقياس الاقتناع. ✦ = مدير منتقى.
المشترون الجدد
| لا يوجد مشترون جدد متابعون هذا الربع. |
تم الخروج
| Norges Bank | $8.83B | كان 1.1% |
| Tiger Global Management | $1.18B | كان 3.5% |
| Viking Global Investors | $325.00M | كان 0.9% |
| Coatue Management | $91.53M | كان 0.3% |
| Duquesne Family Office | $78.48M | كان 2.0% |
| Renaissance Technologies | $204,662 | كان 0.0% |
سياق السوق الكاملة: عبر جميع مودعي 13F (بيانات SEC المنظّمة، Q1 2026): 4,323 المالكون, 762.84M الأسهم, $674.93B مُبلَّغ عنه. هذه فترة مختلفة وأقدم من أرقام الكون المتتبع أعلاه، ولا يتم دمج الاثنين في أي وقت.
ما يحمله حاملو هذا الورقة المالية المتتبعون في أغلب الأحيان — إحصاءات التملّك المشترك، لا علاقات أساسية.
مشتريات السوق المفتوحة (P)
لا توجد مشتريات داخلية في السوق المفتوحة ضمن نافذة التغطية لدينا.
مبيعات السوق المفتوحة (S)
Officer · 6.50K سهم · $7.64M
Officer · 2.00K سهم · $2.37M
Officer · 5.00K سهم · $5.95M
لا تُحتسب هنا الجوائز وعمليات التنفيذ والاستقطاع الضريبي ضمن عمليات الشراء أو البيع. المنهجية
The Food and Drug Administration has cleared a new blood test from Roche and Eli Lilly designed to help identify…
ForbesThe Food and Drug Administration cleared a blood test for identifying Alzheimer's disease symptoms, which was developed…
WSJThe U.S. Food and Drug Administration has cleared Roche and partner Eli Lilly's blood test to help identify signs of…
ReutersThe once-daily pill was approved for patients with a body mass index of at least 30, or between 27 and 30 in the event…
WSJEli Lilly said on Monday it has launched its oral pill, Foundayo, in the UK for weight management and type 2…
Reuters